See more : Music Broadcast Limited (RADIOCITY.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Salarius Pharmaceuticals, Inc. (SLRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Salarius Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- ORIC Pharmaceuticals, Inc. (ORIC) Income Statement Analysis – Financial Results
- Jindal Drilling & Industries Limited (JINDRILL.NS) Income Statement Analysis – Financial Results
- PT Bayu Buana Tbk (BAYU.JK) Income Statement Analysis – Financial Results
- Hello Pal International Inc. (27H.F) Income Statement Analysis – Financial Results
- Friendly Corporation (8209.T) Income Statement Analysis – Financial Results
Salarius Pharmaceuticals, Inc. (SLRX)
About Salarius Pharmaceuticals, Inc.
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 1.84M | 5.23M | 3.47M | 838.00K | 1.28M | 1.01M | 0.00 |
| Cost of Revenue | 10.05K | 6.68K | 19.18K | 6.91K | 4.02K | 431.00K | 507.00K | 663.00K | 49.88K |
| Gross Profit | -10.05K | -6.68K | 1.82M | 5.23M | 3.46M | 407.00K | 768.00K | 348.00K | -49.88K |
| Gross Profit Ratio | 0.00% | 0.00% | 98.96% | 99.87% | 99.88% | 48.57% | 60.24% | 34.42% | 0.00% |
| Research & Development | 7.17K | 15.84M | 8.55M | 6.91M | 4.02M | 11.91M | 16.99M | 20.38M | 12.75M |
| General & Administrative | 5.72K | 7.14M | 6.10M | 6.11M | 7.71M | 2.35M | 1.37M | 797.49K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.22M | 17.14M | 19.06M | 0.00 |
| SG&A | 5.72K | 7.14M | 6.10M | 6.11M | 7.71M | 10.57M | 18.50M | 19.86M | 16.46M |
| Other Expenses | 0.00 | 8.87M | -4.00 | -178.59K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 12.89K | 22.98M | 14.65M | 12.84M | 11.73M | 22.48M | 35.49M | 40.23M | 29.21M |
| Cost & Expenses | 12.89K | 22.98M | 14.65M | 12.84M | 11.73M | 22.91M | 36.00M | 40.90M | 29.21M |
| Interest Income | 352.25K | 218.73 | 0.00 | 0.00 | 15.65K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 3.05K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 10.05K | 6.68K | 19.18K | 18.06K | 16.93K | 16.95K | 324.55K | 277.23K | 49.88K |
| EBITDA | -12.88K | -31.60M | -12.75M | -7.33M | -6.92M | -22.07M | -34.11M | -39.89M | -29.09M |
| EBITDA Ratio | 0.00% | 0.00% | -698.70% | -149.97% | -272.69% | -2,634.13% | -2,723.61% | -3,945.20% | 0.00% |
| Operating Income | -12.89K | -31.84M | -12.81M | -7.79M | -9.58M | -22.07M | -34.73M | -39.89M | -29.21M |
| Operating Income Ratio | 0.00% | 0.00% | -696.27% | -148.78% | -276.37% | -2,634.13% | -2,723.61% | -3,945.20% | 0.00% |
| Total Other Income/Expenses | 352.25 | 233.18K | 44.69K | 434.09K | 1.33M | 152.01K | 291.96K | 393.11K | 72.00K |
| Income Before Tax | -12.54K | -31.61M | -12.77M | -7.35M | -6.94M | -21.92M | -34.43M | -39.49M | -29.14M |
| Income Before Tax Ratio | 0.00% | 0.00% | -693.84% | -140.49% | -200.23% | -2,615.99% | -2,700.71% | -3,906.33% | 0.00% |
| Income Tax Expense | 0.00 | -233.18K | -63.88K | -255.50K | -1.33M | 152.01K | -324.58K | -277.12K | -49.85K |
| Net Income | -12.54K | -31.37M | -12.70M | -7.10M | -5.61M | -21.92M | -34.43M | -39.49M | -29.14M |
| Net Income Ratio | 0.00% | 0.00% | -690.37% | -135.61% | -161.88% | -2,615.99% | -2,700.71% | -3,906.33% | 0.00% |
| EPS | 0.00 | -14.77 | -7.68 | -11.39 | -42.90 | -760.47 | -1.25K | -1.52K | -1.30K |
| EPS Diluted | 0.00 | -14.77 | -7.68 | -11.39 | -42.90 | -760.47 | -1.25K | -1.52K | -1.30K |
| Weighted Avg Shares Out | 3.26M | 2.12M | 1.65M | 623.14K | 130.75K | 28.83K | 27.62K | 25.97K | 22.45K |
| Weighted Avg Shares Out (Dil) | 3.26M | 2.12M | 1.65M | 623.14K | 130.75K | 28.83K | 27.62K | 25.97K | 22.45K |
Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q1 2022 Results - Earnings Call Transcript
Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results
Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration
Salarius Pharmaceuticals to Report First Quarter 2022 Financial Results and Highlight Recent Company Progress
Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering
Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q4 2021 Results - Earnings Call Transcript
Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2021 Financial Results
Salarius Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results and Highlight Recent Company Progress
Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference
Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program
Source: https://incomestatements.info
Category: Stock Reports